<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858559</url>
  </required_header>
  <id_info>
    <org_study_id>HS047</org_study_id>
    <nct_id>NCT00858559</nct_id>
  </id_info>
  <brief_title>Follow-up of Patients With Implantable Cardioverter Defibrillators by Home Monitoring (ANVITE)</brief_title>
  <acronym>ANVITE</acronym>
  <official_title>Follow-up of Patients With Implantable Cardioverter Defibrillators by Home Monitoring (ANVITE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with implantable cardioverter defibrillators (ICDs) should undergo regular device
      follow-ups every 3 months, to verify proper ICD function. However, many follow-ups are
      uneventful, revealing no relevant changes related to the implanted device and in the
      patient's diagnostic and therapeutic status. For time and economic reasons, longer follow-up
      intervals are frequently used although they are not according to recommendations. This may
      increase the delay in detection of relevant changes in the disease and in deviations from
      optimal ICD therapy in the individual patients. In the newest ICDs, the essential parameters
      reflecting safety and appropriateness of ICD therapy (threshold, impedance, intracardiac
      electrogram, etc.) are transmitted via Home Monitoring on a daily basis, to an internet
      platform accessible by the attending physician.

      In the present study, the investigators evaluate safety and efficacy of 12-month follow-up
      intervals in ICDs with Home Monitoring capability, as compared with conventional 3-month
      follow-up scheme.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped due to low enrollment. Patients will be followed up for 3 months.
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant adverse events, especially death, hospitalization, inadequate device therapies</measure>
    <time_frame>27 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of device follow-ups</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Cardiac Pacing</condition>
  <condition>Electric Countershock</condition>
  <condition>Ventricular Tachyarrhythmia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home Monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Home Monitoring not used</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable cardioverter defibrillator with Home Monitoring function</intervention_name>
    <description>Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lumax 500/540 VR-T</other_name>
    <other_name>CardioMessenger (for Home Monitoring data transmission)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard implantable cardioverter defibrillator</intervention_name>
    <description>Implantable cardioverter defibrillators used as standard devices without Home Monitoring</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Lumax 500/540 VR-T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for a single-chamber implantable cardioverter-defibrillator (ICD)

        Exclusion Criteria:

          -  Contraindication for ICD

          -  Indication for dual-chamber ICD or cardiac resynchronization therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Perings, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology in Tangram House, Düsseldorf, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology in Tangram House</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Implantable cardioverter defibrillator</keyword>
  <keyword>Remote monitoring</keyword>
  <keyword>Follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

